ArticleDiseases & research2025
Multifaced Anticancer Potential of Doxorubicin: Spotlight on Breast Cancer.
Article in Diseases & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Rosmarinic Acid Enhances Doxorubicin Activity in MDA-MB-231 Cells: Associations with Intracellular Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis.Biomedicines · 2026Article
- Cytotoxic, Drug-Interaction, and Apoptosis-Associated Effects of β-Boswellic Acid and Doxorubicin in Murine 4T1 TNBC-like Cells.Biomedicines · 2026Article
- Inhibition of Mitochondrial Fission by Mdivi-1 Alleviates Doxorubicin-Induced Nephrotoxicity in a Rat Model of D-Galactose-Induced Accelerated Renal Aging.Biomolecules · 2026Article
- Amifostine Attenuates Doxorubicin-Induced Subacute Hepatic and Renal Toxicity in Rats.International journal of molecular sciences · 2026Article
- Gallic Acid Enhances the Anticancer Activity of Docetaxel in Triple-Negative Breast Cancer Cells.Biology · 2026Article
- Phytocannabinoids as epigenetic regulators: bridging DNA methylation and redox homeostasis in glioblastoma.Journal of applied genetics · 2026Article
- L-Arginine as an Adjuvant Chemosensitizer: Enhancement of Intestinal Permeability and Cytotoxic Activity of Doxorubicin.Pharmaceuticals (Basel, Switzerland) · 2026Article
- NiCo₂O₄ nanoparticles as chemosensitizers: enhancing doxorubicin-ınduced ıntrinsic apoptosis in A549 and MCF-7 cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer is a leading cause of death among women worldwide due to its aggressive nature, early metastasis, and resistance to standard chemotherapy. Doxorubicin (DOX) is a potent anticancer drug and remains one of the most effective treatments for breast cancer. This review delves into the diverse anticancer attributes of DOX, encompassing its ability to induce DNA damage, provoke the production of reactive oxygen species, facilitate various mechanisms of cell death, and promote or enhance an anti-tumor immune response. Through an analysis of both monotherapy and combination therapy approaches, this review underscores the immense significance of DOX in contemporary breast cancer treatment. It also delves into the limitations of DOX-based therapies and provides insights into future perspectives for research and development in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.